DOR BioPharma, Inc. ( DOR ) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR’s lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.
Company Details
- Employees
- 31
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- dorbiopharma.com
- Keywords
- Pharmaceutical Drug Development.
Dor Biopharma, Inc. Questions
Dor Biopharma, Inc.'s website is dorbiopharma.com
Dor Biopharma, Inc.'s LinkedIn profile is https://www.linkedin.com/company/dor-biopharma-inc.
Dor Biopharma, Inc. has
31 employees.
View email and phone details for 31
employees at Dor Biopharma, Inc..
Dor Biopharma, Inc.'s industry is
Biotechnology Research
Dor Biopharma, Inc.'s top competitors are
Abis Foods (A Tsc Product World),
Max Biopharma, Inc.,
Star Biopharma Consulting,
Juventix,
Paramount Capital,
Onezero Solutions,
Avril Biopharma, Inc.,
Precision Biopharma,
Peptinovo Biopharma,
Triangulum Biopharma.
Dor Biopharma, Inc.'s categories are Biotechnology Research
